Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Btissame El Hassouni

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5033042236. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2019: 6 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 11

  1. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. Co-author DOI 10.7150/ijbs.92671↗
  2. The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells. Co-author DOI 10.1080/15257770.2022.2031215↗
  3. Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights. Co-author DOI 10.1002/onco.13606↗
  4. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-01892-z↗
  5. 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/molecules25020329↗
  6. Pharmacogenetics of treatments for pancreatic cancer. Co-author DOI 10.1080/17425255.2019.1620731↗
  7. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. First author DOI 10.1177/1758835919841233↗
  8. Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13508↗
  9. Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivative… Co-author DOI 10.21873/anticanres.13509↗
  10. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Co-author DOI 10.3390/cancers11050638↗
  11. CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage. Co-author DOI 10.3390/molecules24244445↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 11 shared papers, 2019–2024 · strength 1.29
  2. Godefridus J. Peters · 7 shared papers, 2019–2024 · strength 0.85
  3. Niccola Funel · 5 shared papers, 2019–2021 · strength 0.48
  4. Patrizia Diana · 4 shared papers, 2019–2024 · strength 0.47
  5. Daniela Carbone · 3 shared papers, 2019–2024 · strength 0.37
  6. Geert Kazemier M · 3 shared papers, 2019–2021 · strength 0.35
  7. Giovanna Li Petri · 3 shared papers, 2019–2020 · strength 0.29
  8. Stella Cascioferro · 3 shared papers, 2019–2020 · strength 0.29
  9. Barbara Parrino · 3 shared papers, 2019–2020 · strength 0.29
  10. Luca Morelli · 2 shared papers, 2021–2024 · strength 0.28
  11. Tessa Y. S. Le Large · 2 shared papers, 2019–2021 · strength 0.19
  12. Hanneke W.M. van Laarhoven · 2 shared papers, 2019–2021 · strength 0.19
  13. Connie R. Jiménez · 2 shared papers, 2019–2021 · strength 0.19
  14. Maarten F. Bijlsma · 2 shared papers, 2019–2021 · strength 0.19
  15. Annalisa Comandatore · 1 shared paper, 2024 · strength 0.18
  16. Amir Avan · 1 shared paper, 2024 · strength 0.18
  17. Giulia Mantini · 1 shared paper, 2024 · strength 0.18
  18. I Gede Putu Supadmanaba · 1 shared paper, 2024 · strength 0.18
  19. Rocco Sciarrillo · 1 shared paper, 2024 · strength 0.18
  20. Marika Frańczak · 1 shared paper, 2022 · strength 0.16
  21. Jisce R. Puik · 1 shared paper, 2021 · strength 0.16
  22. Alessandro Gregori · 1 shared paper, 2021 · strength 0.16
  23. Dongmei Deng · 1 shared paper, 2021 · strength 0.16
  24. Benoît Immordino · 1 shared paper, 2019 · strength 0.12
  25. Claudio Ricci · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.